COLLEGIUM PHARMACEUTICAL, INC (COLL) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 38 days, typically, give or take 9 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026before open 36 8-K
Q2 FY2026Thu, Aug 6, 2026before open 37 8-K
Q1 FY2026Thu, May 7, 2026before open 37 8-K
Q4 FY2025Thu, Feb 26, 2026before open 57 8-K
Q3 FY2025Thu, Nov 6, 2025before open 37 8-K
Q2 FY2025Thu, Aug 7, 2025before open 38 8-K
Q1 FY2025Thu, May 8, 2025after close 38 8-K
Q4 FY2024Thu, Feb 27, 2025after close 58 8-K

What they guided beta

Q3 FY2026 "Document Exhibit 99.1 Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance – Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS ® Quarterly Net Revenue of $26.5 Million in First Full Quarter of Sales Under Collegium Ownership – – Generated Quarterly Pain Portfolio Net Revenues of $138.0 Million – – Announced $50 Million Accelerated Share Repurchase in Q3’26 – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHT" exhibit
Q3 FY2026 "“We are reaffirming our full-year 2026 financial guidance and remain committed to deploying capital in a disciplined manner, including executing on business development, paying down debt, and opportunistically returning capital to shareholders to create long-term value." exhibit
Q3 FY2026 "The final settlement of the ASR is expected to be completed in the fourth quarter of 2026." exhibit
Q3 FY2026 "Piper Sandler Annual Healthcare Conference – New York, NY; December 1 Financial Guidance for 2026 The Company reaffirms its full-year 2026 guidance for Product Revenues, Net, JORNAY PM Revenue, Net, AZSTARYS Revenue, Net and Adjusted EBITDA: Product Revenues, Net $825 to $855 million JORNAY PM Revenue, Net $190 to $200 million AZSTARYS Revenue, Net $65 to $75 million Adjusted EBITDA $445 to $470 million Financial Results for Quarter Ended September 30, 2026" exhibit
Q3 FY2026 "The Company has not provided a reconciliation of its full-year 2026 guidance for adjusted EBITDA to the most directly comparable forward-looking GAAP measures, in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K, because the Company is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition-related expenses, amortization of acquired intangible assets, and changes in fair value of contingent consi" exhibit
Q2 FY2026 "Document Exhibit 99.1 Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress – Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated JORNAY PM® Quarterly Net Revenue of $46.1 Million, Up 41% Year-over-Year – – Generated AZSTARYS Quarterly Net Revenue of $12.9 Million, Representing a Partial Quarter of Sales – – Generated Quarterly Pain Portfolio Net Revenues of $140.9 Million – – Updates Full-Year 2026 Financial " exhibit
Q2 FY2026 "The acquisition adds a highly complementary and differentiated ADHD medicine with significant growth potential and expected patent protection through 2037." exhibit
Q2 FY2026 "Wainwright 28th Annual Global Investment Conference – New York, NY; September 16, 2026 Financial Guidance for 2026 Collegium reaffirms its full-year 2026 guidance for JORNAY PM and raises AZSTARYS Revenue, Net and updates its full-year 2026 guidance for Product Revenues, Net, and Adjusted EBITDA." exhibit
Q2 FY2026 "The Company has not provided a reconciliation of its full-year 2026 guidance for adjusted EBITDA to the most directly comparable forward-looking GAAP measures, in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K, because the Company is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition related expenses, amortization of acquired intangible assets, and changes in fair value of contingent consi" exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/COLL
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/COLL

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

COLL earnings date badge

HTML

<a href="https://veritasdata.dev/company/COLL/"><img src="https://veritasdata.dev/embed/COLL.svg" alt="COLL earnings date" width="240" height="56"></a>

Markdown

[![COLL earnings date](https://veritasdata.dev/embed/COLL.svg)](https://veritasdata.dev/company/COLL/)

Script

<script async src="https://veritasdata.dev/embed/COLL.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/COLL"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.